A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.

Authors

Eric Christenson

Published

June 1, 2024

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Pathology And Forensic Medicine

DOI

10.1200/jco.2024.42.16_suppl.2538

A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.

Authors

Eric Christenson

Published

June 1, 2024

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Pathology And Forensic Medicine

DOI

10.1200/jco.2024.42.16_suppl.2538

Paper

Paper

Paper

Paper

A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.

Supporters

Journal

Topics

DOI

A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.

Supporters

Journal

Topics

DOI